Actively Recruiting
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Led by AstraZeneca · Updated on 2025-02-07
210
Participants Needed
32
Research Sites
109 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
CONDITIONS
Official Title
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed hepatocellular carcinoma by tissue pathology or imaging
- No previous systemic therapy for hepatocellular carcinoma
- Barcelona Clinic Liver Cancer (BCLC) stage B not eligible for local therapy, or stage C
- Child-Pugh liver function class A or B
- ECOG performance status 0 to 2 at enrollment (class A and ECOG 0-1 in cohort 1, class B or ECOG 2 in cohort 2)
- At least one measurable tumor lesion according to RECIST 1.1 guidelines
You will not qualify if you...
- History of hepatic encephalopathy within past 12 months or needing medication for it
- Clinically significant ascites (fluid buildup in the abdomen)
- Main portal vein tumor thrombosis
- Active or recent gastrointestinal bleeding within past 6 months
- Co-infection with HBV and HCV or HBV and Hepatitis D
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 32 locations
1
Research Site
Beijing, China, 100021
Active, Not Recruiting
2
Research Site
Beijing, China, 100142
Active, Not Recruiting
3
Research Site
Beijing, China, 211405
Active, Not Recruiting
4
Research Site
Beijing, China, CN-100730
Active, Not Recruiting
5
Research Site
Changsha, China, 410005
Completed
6
Research Site
Changsha, China, 410013
Active, Not Recruiting
7
Research Site
Chengdu, China, 610041
Active, Not Recruiting
8
Research Site
Fuzhou, China, 350011
Active, Not Recruiting
9
Research Site
Guangzhou, China, 510060
Active, Not Recruiting
10
Research Site
Guangzhou, China, 510100
Active, Not Recruiting
11
Research Site
Guangzhou, China, 510260
Active, Not Recruiting
12
Research Site
Guangzhou, China, 510515
Active, Not Recruiting
13
Research Site
Hangzhou, China, 310022
Active, Not Recruiting
14
Research Site
Harbin, China, 150081
Active, Not Recruiting
15
Research Site
Jinan, China, 2501117
Actively Recruiting
16
Research Site
Nanjing, China, 2100008
Active, Not Recruiting
17
Research Site
Nanjing, China, 210009
Active, Not Recruiting
18
Research Site
Nanjing, China, 210029
Active, Not Recruiting
19
Research Site
Ningbo, China, 315010
Active, Not Recruiting
20
Research Site
Shanghai, China, 200032
Active, Not Recruiting
21
Research Site
Shanghai, China, 200040
Active, Not Recruiting
22
Research Site
Shenyang, China, 110001
Active, Not Recruiting
23
Research Site
Tianjin, China, 300000
Active, Not Recruiting
24
Research Site
Tianjin, China, 300060
Withdrawn
25
Research Site
Tianjin, China, 300170
Withdrawn
26
Research Site
Wenzhou, China, 325000
Active, Not Recruiting
27
Research Site
Wuhan, China, 430022
Active, Not Recruiting
28
Research Site
Wuhan, China, 430079
Active, Not Recruiting
29
Research Site
Xi'an, China, 710038
Active, Not Recruiting
30
Research Site
Zhangjiagang, China, 215699
Active, Not Recruiting
31
Research Site
Zhengzhou, China, 450000
Withdrawn
32
Research Site
Zhengzhou, China, 450008
Active, Not Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here